Other Guidelines | Page 33 | European Cystic Fibrosis Society (ECFS)

Measuring how the drug elexacaftor/tezacaftor/ivacaftor affects the muscles of breathing, using dynamic chest radiography

Results from a clinical trial of the natural therapeutic alginate OligoG against Burkholderia lung infection in people with cystic fibrosis.

Bacterial communities relate to gut function and transit in the cystic fibrosis gut

Advanced but not mild liver disease is a predictor of decreased survival in children with cystic fibrosis, with far greater impact in females: A 27-year real-life cohort study

Antisense oligonucleotide as a novel therapy for people with CF affected by the W1282X mutation

Guidance for Sweat Testing in Europe

Elexacaftor-tezacaftor-ivacaftor provides continued health improvement in lung transplant candidates with cystic fibrosis

Exploring health care provider attitudes and perspectives related to men’s sexual and reproductive health in cystic fibrosis

Looking at lung disease over time in young children with CF

Looking at lung disease over time in young children with CF

first
previous
…
29
30
31
32
33
34
35
36
37
…
next
last